Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of Amicus Therapeutics, Inc.
Teva Pharmaceutical Industries Ltd. announced the exclusive launch of generic capsules in the...
According to Hemp, Inc., the Hemp Industry continues to garner media attention.
A new report estimates that a majority of needed manufacturing jobs could go unfilled over the...
Aridis Pharmaceuticals, Inc., announced that it has secured several grants which bring Aridis' total non-dilutive funding in excess of $40 million.
IGI Laboratories, Inc., announced it has entered into an agreement to acquire the assets of a Canadian pharmaceutical company for $47 million CAD in cash.
Peak Pharmaceuticals, Inc., announced the termination of its licensing agreement with Canna-Pet, LLC.
Orders for manufacturing technology equipment in the U.S. in August were down, according to the latest U.S. Manufacturing Technology Orders report.
Sugar beet and seaweed aren’t the first things that spring to mind when you start thinking about the latest and most promising drugs. But without them, a new class of revolutionary medicines called biologics targeting everything from diabetes and cancer to arthritis and immune disorders would be extremely hard to make.
Amazon.com last week announced plans to join the wave of tech companies investing in the Internet of Things.
Taiho Oncology Inc.'s combination tablet, recently approved by the FDA, will be dispensed by Diplomat Pharmacy.
Adaptimmune Therapeutics plc. announced plans to locate its U.S. headquarters and clinical operations in a newly developed facility to be constructed in Philadelphia.
Sunshine Biopharma Inc. announces that it has acquired a U.S. patent.
Medline Industries, Inc. announced that it will initiate a voluntary nationwide recall of lot of tablets.
Ohio sent a forceful letter to Washington on Friday asserting that the state believes it can obtain a lethal-injection drug from overseas without violating any laws.
Bristol-Myers Squibb Company announced that the FDA has approved their drug, for intravenous use, for the treatment of patients with metastatic NSCLC with progression on or after platinum-based chemotherapy.
Vertex Pharmaceuticals Incorporated announced that the FDA has accepted for review a sNDA for a drug that treats CF in people ages 2 and older who have one of 23 residual function mutations.
Nektar Therapeutics announced that it has submitted an IND application to the FDA for its lead immuno-oncology candidate.
Marathon Pharmaceuticals announced that the FDA has granted rare pediatric disease designation for a potential treatment for patients with DMD.